Bioteque Corporation

As of June 30, 2026, Bioteque Corporation carries a market capitalization of 7.97B, placing it among publicly traded companies globally. Its enterprise value stands at 6.60B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Bioteque Corporation's next confirmed earnings release is scheduled for November 17, 2026.

As of June 30, 2026, Bioteque Corporation has 69.30M shares outstanding.

As of June 30, 2026, Bioteque Corporation trades at a trailing price-to-earnings ratio of 13.52. The price-to-sales ratio is 3.59, and the price-to-book ratio stands at 2.26.

As of June 30, 2026, Bioteque Corporation trades at an EV/EBITDA multiple of 7.38 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.97 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 9.15 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Bioteque Corporation trades at an EV/FCF ratio of 11.00, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 6.60B versus a market cap of 7.97B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Bioteque Corporation maintains a current ratio of 2.75, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.16, indicating elevated leverage, while an interest coverage ratio of 131.08 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Bioteque Corporation posted a return on equity (ROE) of 17.29, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 13.87 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 12.24, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 14.88, useful for judging operating efficiency across full business cycles. The company generates approximately 4.54M in revenue per employee across its workforce of 489.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.11 indicates how many times Bioteque Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Bioteque Corporation recorded 162.68M in income tax expense. That works out to an effective tax rate of 21.63, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 752.12M, leaving 589.44M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Bioteque Corporation's stock has declined approximately 12.20% over the past 52 weeks. The 50-day moving average sits at 111.79, while the 200-day moving average is 116.68.

Over the twelve months ended June 30, 2026, Bioteque Corporation generated 2.22B in revenue and converted that into 589.44M in net income, yielding earnings per share of 8.46. EBITDA reached 893.70M, while operating income came in at 720.90M.

As of June 30, 2026, Bioteque Corporation holds 1.87B in cash and equivalents against 499.42M in total debt, resulting in a net debt position of -825.99M. Total book value stands at 3.53B, with working capital of 1.63B providing operational flexibility.

Bioteque Corporation produced 703.17M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -108.84M in capital expenditures, free cash flow totaled 594.33M - equivalent to 8.57 per share.

Over the twelve months ended June 30, 2026, Bioteque Corporation posted a gross margin of 45.15, reflecting its pricing power and cost economics. The operating margin of 32.46 and net profit margin of 26.54 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Bioteque Corporation paid dividends of 5.00 per share. The dividend payout ratio of 58.78 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 7.42, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 6.69, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Bioteque Corporation shareholders.

Bioteque Corporation's most recent stock split took place on September 2, 2015 with a 291:233 split ratio.

As of June 30, 2026, Bioteque Corporation has an Altman Z-Score of 5.40, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.